Complete seizure control is achieved in 40-50% of all epileptic patients with drug treatment, as reported in most epidemiological studies. Many effective antiepileptic drugs with a favourable profile are available in Switzerland, allowing treatment tailored to the patient's needs. Unfortunately, up to 40-50% of all patients will eventually relapse (pharmacoresistant epilepsy). These patients run a high risk of additional morbidity and mortality. Possible pharmacoresistant epilepsy should be considered early in the disease, when there is a lack of response to the first antiepileptic drug, since only 14% of those will respond to a second drug, and only 2% to a third drug if the second fails too. Epilepsy surgery is a viable option for these patients. It requires in-depth evaluation in specialized centres, and is related to complete seizure control in 50-90% of the patients, depending on the lesion type and site. Only for patients in whom surgery cannot be offered should neuromodulation treatments be considered. Today, two different approaches are approved, vagal nerve stimulation (VNS) and deep brain stimulation in the anterior thalamic nuclei (DBS-ANT). Although only a minority of patients become totally seizure-free. Both VNS and DBS-ANT represent an important adjunct in the therapeutic armamentarium. In the present review, we outline a practical approach for the different steps in therapeutic decisions and we summarise the profiles of modern antiepileptic drugs as well outcome of surgical and neuromodulatory therapies. The goal of any approach should be to obtain complete seizure control. In general, if two antiepileptic drugs are not successful, in-depth evaluation of the patient in a specialised center is strongly recommended. 
Introduction
The prevalence of epilepsy is 0.5-1%, with an overall rate of complete seizure control in 40-50% of epileptic patients. "Epilepsy" has to be differentiated from acute symptomatic seizures (table 1) and diseases that mimic epileptic seizures (table 2) . Acute symptomatic seizures, previously also called "provoked seizures", do not meet the criteria of this definition, and therefore do not represent "epilepsy". Table  1 gives an overview of the most frequent acute insults. In the majority of cases, they do not need antiepileptic treatment (exceptions include recurrent alcohol withdrawal or other recurrent acute toxicometabolic conditions that cannot be controlled).
The new definition of epilepsy no longer requires the occurrence of two seizures (table 3) , but rather one seizure plus an enduring high likelihood that a second seizure will occur, if the patient is not treated accordingly [3] . This is the case, for example, in a patient whose first seizure led to the discovery of a tumour on magnetic resonance imaging (MRI), or an 18-year-old with generalised polyspikewave discharges under hyperventilation on a standard electroencephalogram (EEG), indicating the presence of juvenile myoclonic epilepsy. The new definition of epilepsy changes the interpretation of older epidemiology studies, which still used the definition of two spontaneous seizures within >24 h, but matches clinical experience in most cases [4] . Especially, the important question of when to introduce an antiepileptic treatment is still subject of ongoing discussion. In 2015, the American Association of Neurology issued new recommendations [5] , giving level A evidence for an increased chance of a recurrent seizure for adult patients, greatest within the first 2 years after a first seizure (21-45%). However, evidence in favour of risk reduction when directly starting antiepileptic drug (AED) therapy, as compared with a delay of treatment pending a second seizure, is only level B, compared with level B evidence for a 7-31% incidence of adverse effects from AED therapy, but which are mild and reversible. There is only weak evidence that immediate AED therapy, as compared with awaiting a second seizure, may not improve quality of life (level C) [6] . It has been claimed that some of this evidence is based on a very few old studies [7] . In the case of prior brain insult such as stroke or trauma, as well as in the presence of epileptiform abnormalities on the EEG, evidence is level A for the increased risk for seizure recurrence. However, for the association of clinical factors such as brain-imaging abnormality or a nocturnal seizure, evidence is only level B. The guideline's summary conclusion is therefore that "… recommendations whether to initiate immediate AED treatment after a first seizure should be based on individualized assessments that weigh the risk of recurrence against the AEs [adverse events] of AED therapy, consider educated patient preferences, and advise that immediate treatment will not improve the long-term prognosis for seizure remission but will reduce seizure risk over the subsequent 2 years." [6] This emphasises that guidelines summarise current evidence, but cannot replace individual judgment in the case of every specific patient [7] .
The aim of any epilepsy therapy should always be the suppression of all seizures. Drug studies showed that 40-50% of patients with focal epilepsy, and about 15% of patients with idopathic generalised epilepsy (in the new terminology now called "genetic generalised epilepsy") are refractory to medical treatment. Pharmacoresistant epilepsy (PRE) is diagnosed if two or more AEDs do not lead to complete seizure control, despite regular drug intake of sufficiently high dosages as determined by regular measurement of serum levels (preferentially in the morning or before next drug intake). The chance to control seizures with a third drug is only 2% [8] . There are several reasons why drugs do not work (table 4) . Therefore, PRE requires prompt evaluation to determine possible reasons, usually as an inpatient evaluation. 
Conceptual definition of seizure and epilepsy -2014 ILAE Annual Report
An epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain.
Epilepsy is a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures, and by the neurobiological, cognitive, psychological and social consequences of this condition. The definition of epilepsy requires the occurrence of at least one epileptic seizure.
From [4] . While surgery can cure epilepsy, neuromodulation -up to now -is a palliative treatment strategy giving freedom from seizures in <10% of the cases. In both cases, careful evaluation in specialised centres is necessary to obtain a clear picture of the underlying syndrome and information on the chance for benefit from these alternative therapeutic strategies.
A practical approach to modern epilepsy care is summarised in figure 1 .
In the present article, we summarise the most clinically relevant data on the newer AEDs (i.e., introduced after 1997) In-patient evaluation in specialized centre: is epilepsy surgery possible?
Figure 1
Practical approach to modern epilepsy care.
in alphabetical order, as well as epilepsy surgery and neuromodulation available in Switzerland: vagal nerve stimulation (VNS) and deep brain stimulation in the anterior thalamic nuclei (DBS-ANT). . Oxcarbazepine might also be associated with this risk; however, there is currently insufficient data to support a recommendation for testing the presence of both alleles in patients prior to treatment. There is also ongoing discussion of the cost-benefit of a regular HLA testing, given the high costs of the test, that this complication is extremely rare and that most patients in Switzerland are clinically monitored by their neurologists or family doctors.
Antiepileptic drugs
In 1994 lamotrigine and in 1996 topiramate became available, both with a wide spectrum, for children and as monotherapy. Lamotrigine is very well tolerated in doses up to 500-700 mg (as monotherapy), and has a favourable effect on mood and cognitive functions. However, it requires very slow introduction extending over 2 months and more, which is not convenient in patients with a high seizure count. Also the high incidence of allergies was an issue during early use of the molecule, but can be largely avoided if this slow titration route is chosen. Topiramate is known for its anorexic effect (noted in around 20% of patients) due to decreased appetite. In some patients and children this can be severe, requiring drug withdrawal. Other side effects are hyperthermia, irritability and depression (which is the reason why it is sometimes used for mania). Rarely, glaucoma or kidney stones are also described. Topiramate probably has teratogenic effects, in particular in polytherapy [14, 15] . The most teratogenic AED is valproate, and children exposed in utero to valproate are at a high risk of major developmental disorders and congenital malformations (10% of cases 
Lacosamide -Vimpat®
Lacosamide is a sodium-channel modulator with a different mechanism of activity from the other known sodium-channel blockers like carbamazepine, lamotrigine or phenytoin. Unlike those drugs, lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels without affecting their fast inactivation [17] . This normalises activation thresholds and therefore controls neuronal hyperexcitability and pathological neuronal activity [17] . Lacosamide was approved by the US Food and Drug Administration (FDA) in 2007 and has been available in Switzerland since 2009 as add-on therapy in adult patients with focal seizures with and without secondary generalisa- Uncertain -reduces Na + channel activity
Frequent adverse effects
Dizziness, somnolence, irritability, headache, ataxia
Weight gain, somnolence, dizziness, irritability Headache, dizziness, fatigue, nausea, somnolence, diplopia nasopharyngitis, tremor. 
Oral contraception

Levetiracetam -Keppra® and generics
The exact mechanism of action of levetiracetam is unknown, but it appears that its affinity to the synaptic vesicle protein 2A seems to play a crucial role, in that it inhibits presynaptic calcium channels [25] . This synaptic vesicle protein is involved in vesicle exocytosis and neurotransmitter release [26] . Levetiracetam was approved by the FDA in 1999 and has been available in Switzerland since 2000 as add-on therapy (for patients ≥4 years of age) and since 2008 also as monotherapy in focal-onset seizures (>16 years) as well as an adjunctive therapy for primary generalised epilepsy onset (≥12 years). It is available as tablets, syrup and an intravenous solution, making it nowadays one of the most widely used first-line AEDs, including for status epilepticus [27, 28] . The effective dose of levetiracetam varies between 1000 mg and 3000 mg. Levetiracetam is not bound to plasma proteins and is not metabolised in the liver [29] . Elimination is renal and therefore its dosage needs adaptation to the creatinine clearance. The half-life is around 7 h. Levetiracetam is not extensively metabolised, only 25% undergoes enzymatic hydrolysis of the acetamide group by a plasma hydroxylase. It has no known clinically significant pharmacological interactions [30] . A study of oral anticoagulants showed that the prothrombin time international normalised ratio (INR) values measured after repeated administration of placebo or levetiracetam were not statistically different [31] .
Levetiracetam is well tolerated. Side-effects include somnolence and, especially, behavioural changes of varying intensity in around 15%. [32] . In particular, patients with learning disabilities may occasionally show an increase in aggressive behaviour [33, 34] . However, the psychiatric side effects resolve quickly after drug discontinuation.
Oxcarbazepine -Trileptal®, Apydan®
Oxcarbazepine is a keto-analogue of carbamazepine, with a similar spectrum of anticonvulsive activity and efficacy: it blocks voltage-gated sodium channels, potentiates potassium conduction and inhibits calcium channels and Nmethyl-D-aspartate (NMDA) receptors. Oxcarbazepine has been available in Switzerland since 1997. It is used as monotherapy [35] [36] [37] or add-on therapy [40] for focal-onset seizures with or without secondary generalisation in adults [37] [38] [39] and children aged >1 month [40, 41] . It was shown to be equivalent to carbamazepine and phenytoin in its efficacy with a higher tolerability (class I and II evidence) [42, 43] . Oxcarbazepine is available as tablets or an oral suspension, with dosages up to 1800-2400 mg/d [38] . Previous treatment with carbamazepine can be switched to oxcarbazepine rapidly in a 2:3 fashion: 400 mg carbamazepine should be replaced by 600 mg oxcarbazepine [44] . In patients receiving additional AEDs other than carbamazepine, a gradual switch over 2-3 weeks is more appropriate [38] . Oxcarbazepine is metabolised mainly through reductive biotransformation and glucuronidation to the active 10-monohydroxy derivate, the pharmacologically active metabolite [45] . It is eliminated via the liver; it inhibits CYP2C19 and induces CYP3A4, therefore carbamazepine, phenytoin, phenobarbital and valproic acid can lower oxcarbazepine levels, whereas oxcarbazepine may lower phenobarbital and phenytoin levels [46] . Oxcarbazepine is generally well tolerated, except by patients with myoclonic and absence epilepsy, which can be worsened under oxcarbazepine treatment [47] . Adverse effects are similar to those known from carbamazepine, although less severe and less frequent [38, 48, 49] . Due to its effect on antidiuretic hormone in the distal convoluted tubule of the kidney, hyponatraemia is a well-known adverse effect. It is usually asymptomatic and returns to normal with fluid restriction, dose reduction or oxcarbazepine discontinuation [50] .
Perampanel -Fycompa®
Perampanel is a noncompetitive selective blocker of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor, acting on post-synaptic glutamate transmission [51] . Perampanel was FDA-approved in 2012 and has been available in Switzerland since the end of 2013. It is used as add-on treatment of focal-onset seizures in patients ≥12 years of age [51] [52] [53] [54] . In the European Union, but not in Switzerland, perampanel has recently been licensed for the adjunctive treatment of genetic tonic-clonic seizures following the promising results of multicentre, double-blind study [55] . A long-term safety study lasting 3 years showed good tolerability [54] . Perampanel is primarily metabolised in the liver via CYP3A4 and also CPY3A52. However, it only weakly affects the activities of some cytochrome P450 isoenzymes. CYP3A4 inhibitors/inducers affect the availability of perampanel: carbamazepine, oxcarbazepine, and phenytoin reduce perampanel serum levels by about 67%, 50% and 50%, respectively, all of which are considered clinically [58] . Note that with the FDA approval a special warning was issued concerning "serious psychiatric and behavioural adverse reactions including aggression, hostility, irritability, anger and homicidal ideation", however, in a follow-up study neuropsychiatric adverse effects occurred in only a small percentage [59] . And in a very recent review of patients' safety and efficacy during perampanel treatment [60] , slow introduction and close clinical monitoring was recommended in order to prevent these effects and guarantee an overall excellent tolerability.
Pregabalin -Lyrica® and generics
Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-amino-butyrate (GABA). Its effect is supposed to be based on its action on the alpha2 delta subunit of the P/Q-type voltage-sensitive calcium channels, which are present in presynaptic neurons and modulate depolarisation-induced calcium influx [61, 62] . Pregabalin has been available in Switzerland since 2005 as add-on therapy of focal seizures with or without generalisation in adults (>18 years), but is also indicated for the treatment of neuropathic pain, fibromyalgia and generalised anxiety. Dosages of 150-600 mg/d are used. Pregabalin is not protein bound and is eliminated unchanged by renal excretion. Careful monitoring of creatinine clearance is therefore mandatory, even in moderate renal failure. The bioavailability of pregabalin is 90%. Given a half-life of approximately 6 hours, pregabalin can be given in two or three divided doses. Pregabalin had a low risk of drug-drug interactions when added to phenytoin, valproate or lamotrigine [63] . Most common adverse effects reported were somnolence, dizziness, ataxia, diplopia and weight gain. Irritability and euphoria are also described frequently. Most of them tend to resolve with slow continuation of treatment. For women using oral contraception, no adaptation of treatment is necessary; oral contraceptives remain effective under pregabalin. No data are available to our knowledge about its use in patients taking anticoagulants, but theoretically there should be no significant interaction.
Rufinamide -Inovelon®
The exact mechanisms of action of rufinamide are not yet elucidated. Most evidence suggests that rufinamide, a triazole derivative, reduces the capacity of sodium channels to recover from inactivation and limits sodium-dependant action potential firing [64] . Rufinamide has been available in Switzerland since 2009 as add-on therapy for Lennox-Gastaut syndrome in patients aged 4 years or older [65] . The dosage is 400-3200 mg/d. Elimination is predominantly via the renal pathway (85%), although it does not seem to be affected by renal impairment. Rufinamide is 34% plasma protein bound, the majority to albumin. There is no study in patients with severe hepatic dysfunction [64] . Being a triazole derivative, rufinamide is extensively metabolised by non-CYP450 systems (it is a weak inhibitor of CYP2E1 and a weak inducer of CYP3A4), with a half-life of 8-12 h. Rufinamide increases the serum levels of phenytoin and valproate. Since valproate reduces the clearance of rufinamide, lower doses are recommended (i.e. 600-1200 mg/d). In contrast, the effects of rufinamide might be less in patients who take carbamazepine [66] . Important interactions with oral contraceptives must be mentioned to the patient and caregiver, although the precise mechanism is unknown. Adding a second contraceptive device is therefore recommended to protect against pregnancy during rufinamide therapy. Rufinamide was well tolerated at dosages up to 1600 mg/ d. Adverse effects are dose-dependent and more frequent with higher doses. Pooled analysis of all data revealed the following adverse effects with a frequency >10%: headache, dizziness, fatigue, nausea, somnolence, diplopia, nasopharyngitis and tremor. The most frequent adverse events were somnolence (24.3% with rufinamide vs 12.5% with placebo) and vomiting (21.6% vs 6.3%) [65] . No worsening of cognitive function was found after 12 weeks of rufinamide treatment with daily doses of up to 1600 mg [67] .
Zonisamide -Zonegran®
Zonisamide is a benzisoxazol derivative and sulfonamide, and has a wide spectrum of actions, among which are increased GABA release [68] , inhibition of voltage sensitive sodium-channels [69] and T-type calcium-channels, as well as a reduction of potassium-mediated glutamatergic transmission [70, 71] . The inhibition of carbonic anhydrase does not contribute to the antiepileptic effect [72] [73] [74] . A previous US study (with doses of 300-500 mg) was halted because of an increased incidence of renal calculi (3.5%) [75] . Follow-up studies could not confirm this observation; however, avoiding zonisamide in patients with recurrent renal calculi is suggested. The FDA approved zonisamide in 2000, although it has been well established in Japan since 1989, where it is used with success in a variety of seizure types, focal and nonfocal tonic-clonic, tonic, clonic, atonic and myoclonic seizures as well as typical and atypical absences, with responder rates of around 55% for all seizure types together [76] . In Switzerland, zonisamide has been available since 2006 as add-on therapy of focal-onset seizures with or without secondary generalisation (age ≥6 years) and since 2014 also as monotherapy for partial seizures in adults (≥18 years). The dosage is usually between 300 and 500 mg/d (1 mg/kg in children), but patients may already respond at daily doses of 150-200 mg. Zonisamide is eliminated via the renal pathway (97%) and only marginally via the liver (3%); however, it is extensively metabolised by the liver and 15-30% of zonisamide is excreted unchanged via the kidneys. Therefore, zonisamide is contraindicated in moderate to severe renal insufficiency (creatinine clearance of 50 ml/min or less) and also in patients with hepatic insufficiency (Child-Pugh B or C). Conversely, there is neither induction nor inhibition of CYP450 isoenzymes and no self-induction of metabolism [77] , and there is no interaction with other AEDs. Zonisamide is therefore well suited to being added to a multidrug regimen, including older AEDs depending on the CYP450 system. The only exception is topiramate, with which co-medication is currently not recommended: Some adverse effects resemble those of topiramate, zonisamide and topiramate both having an inhibitory effect on carbonic anhydrase and inducing metabolic acidosis and urinary alkalosis, which increases the risk of renal calculi [77] . Zonisamide and topiramate also commonly induce oligohydrosis with hyperthermia (especially in children), due to an inhibition of the carbonic anhydrase isoenzymes I and II and aquaporin-1 (AQP-1), localised in the human exocrine sweat gland. Like topiramate, zonisamide can lead to weight loss, which is a "positive" side effect in overweight patients: 22% of the patients lost >2.3 kg during one study [78] . However, in the majority of patients, no significant change in weight is observed. The other most frequently reported adverse effects of zonisamide were fatigue/somnolence, dizziness, nausea, irritability and ataxia [78] .
It is noteworthy that a study on teratogenicity in humans showed two malformations, anencephaly and atrial septal defect, in 26 studied pregnancies [79] . In animals some teratogenic effects have been demonstrated, but the malformation rate is still unclear given that they were seen in polymedicated patients only.
Others
Eslicarbazepine -Zebinix®
Eslicarbazepine acetate was accepted by the FDA in June 2009, and in most European countries, but approval in Switzerland has not been obtained so far. Since patients with this drug may enter Switzerland and require care, we briefly discuss this drug. Eslicarbazepine has mechanisms of action distinct from carbamazepine and oxcarbazepine, and demonstrated anticonvulsant properties with a wider (1.5-to 2.5-fold) protective index than carbamazepine [80] . Eslicarbazepine is the L-enantiomer of the active compound 10-monohydroxy-carbazepine (li-carbazepine). The R-enantiomer (which causes the adverse effects of carbamazepine and oxcarbazepine, especially hyponatraemia) accounts for less than 10%. Therefore, there was initially hope that hyponatraemia would occur less frequently than with carbamazepine and oxcarbazepine; however, it appeared to be noted to a similar extent [81] [82] [83] [84] . However, unlike carbamazepine, it is less susceptible to enzyme induction or autoinduction. Other adverse effects are comparable to those of carbamazepine and oxcarbazepine. Note that eslicarbazepine interacts with oral contraceptives, so complementary contraception is recommended. Eslicarbazepine metabolites are eliminated primarily by renal excretion. Moderate hepatic impairment has no clinically relevant effect on eslicarbazepine pharmacokinetics [82] , and consequently no dose adjustment is required in patients with mild to moderate hepatic impairment. However, adjustment of the daily dose is recommended for patients with impaired renal function (creatinine clearance <50-60 ml/min) [85] . Eslicarbazepine has a long half-life of 20-24 h, so a single dose per day (mostly 800-1600 mg) may be sufficient.
Polytherapy
If the first monotherapy does not lead to seizure control, combination of drugs is often the first option. However, there are only a few studies on effective "rational" polytherapies. A recent large retrospective study on >8000 patients suggested that combining drugs with different modes of action is more efficient as measured by treatment persistence, number of hospitalisations or emergency room visits, than combining those with similar modes of action [86] . While this has been taught already for some time, it had never been shown in a real-life setting. Overall, polytherapy is not necessarily more toxic, as has been shown in an elegant study with valproate and carbamazepine [87] . However, in this study dosages were low and may explain the lack of difference between carbamazepine monotherapy and combination therapy. In any case, therapeutic drug monitoring is strongly recommended whenever adding or removing a drug, including non-AEDs. Break-through seizures should be avoided as much as possible: they may cost the patients their driver's licenses or cause professional and physical disadvantages. The only combination which was found to be truly synergistic was the combination of lamotrigine and valproate [88] . Addition of valproate to a lamotrigine regimen was much more effective than the addition of phenytoin to a carbamazepine regimen. Moreover, when patients were switched back to monotherapy, lamotrigine was less effective than in combination. This effect is most likely due to the fact that carbamazepine and phenytoin decrease the level of lamotrigine, whereas valproate increases it, i.e. more often at more efficient levels. Effective polytherapy with more than two drugs leading to seizure-free patients included a combination of several broad-spectrum AEDs such as lamotrigine, levetiracetam or valproate, as shown in a larger retrospective study, which should be preferred to drugs with a narrower spectrum, like oxcarbazepine [89] .
Epilepsy surgery
Approximately 40% of all epilepsy patients do not attain freedom from seizures despite regular drug intake in sufficiently high dosages [8] . In these cases, in-depth evaluation is mandatory, to determine the reasons of the non-response to drugs. It should be considered if two AEDs do not result in seizure freedom, i.e. complete control of all seizures, which represents a significant handicap for the patient regarding his or her socio-professional activities and physical integrity. It is of note that exclusively nocturnal seizures also represent a danger, due to an increased risk of suffocation and sudden unexpected death [90] . Patients with chronic epilepsy have a 3-10-fold higher probability of mortality compared with their nonepileptic peers of similar age, depending on the precise underlying syndrome [8, 91, 92] . In an older study, those with right temporal epilepsy had a 30-fold increased risk of mortality [93] , probably because the right insular cortex, crucial in the cerebral control of heart rhythm (bradycardia), is easily recruited during a seizure. However, there is still reluctance towards epilepsy surgery among caring physicians [94, 95] . Two studies [94, 95] have showed that the most frequent causes include underestimation of the danger of recurrent seizures, underestimation of the success rate of epilepsy surgery, overestimation of the complication rate of the surgery, and unclear criteria when to refer. For example, in a study among American neurologists, 19% thought that their patients had to fail all approved AEDs to be considered medically refractory and 55% considered surgery only if the patient had more than one seizure per month [94] . However, three generalised tonic-clonic seizures per year represent also a significant danger for the patient.
Presurgical evaluation with noninvasive techniques (phase I)
The high risks of uncontrolled epilepsy and the low yield of addition of a fourth or fifth AED speak in favour of an evaluation for epilepsy surgery in order to determine the optimal resection site and extent, determine the prognosis for success and verify the absence of non-epileptic events mistaken for epileptic fits. No epilepsy surgery should be undertaken without preceding in-depth evaluation. During the evaluation, two basic questions have to be answered: the location of the epileptic focus and identity of possibly adjacent vital cortex. The goal of epilepsy surgery is safe removal of the epileptogenic tissue without inflicting a (new) neurological deficit. Neurological, neuropsychological and psychiatric evaluations are basic elements of the preoperative work-up. The evaluation procedure includes the recording of several habitual seizures with longterm video-EEG monitoring in a specialised centre, with 24-h surveillance by specialised personnel, rapid access to intensive care and emergency CT. A high resolution MRI scan and, if possible, examination with other imaging tools (e.g. position-emission tomography [PET], single photonemission-computer-tomography [SPECT], high-density EEG / electric source imaging [ESI] ) are crucial in the identification of the seizure onset zone [96] . The more imaging examinations are concordant, the more likely there will be postoperative seizure freedom [97] . Figure 2 provides an example of multimodal imaging in a patient with bitemporal discharges. Surgical results depend critically on the definition of the ictal and interictal EEG onset zone as well as on the presence of a lesion in 1.5-Tesla or, better, 3-Tesla high-resolution MRI, obtained with an epilepsy protocol, i.e. 1 mm slices for most sequences, as detailed elsewhere [98] . If the lesion is highly suspected or functionally localised with PET, SPECT or ESI, but not visualised in the high-resolution MRI, additional statistical analysis of the MRI may be useful and unravel the underlying epileptogenic lesion [99, 100] (fig. 3 ).
Invasive intracranial exploration (phase II)
In some cases, the seizure onset region cannot be determined with sufficiently high certainty with noninvasive tools, so intracranial EEG with implanted electrodes is proposed.
The need to turn towards intracranial EEG depends crucially on the yield of the complementary imaging tools: the clearer the result in the noninvasive image modalities, the lower the need to implant patients with intracranial electrodes. In our centre Geneva-Vaud, this affects only around 15% of all patients; and for the majority of patients, noninvasive imaging tools are sufficient to determine eligibility for surgery. Intracranial exploration has certain important limits, because of the fact that implanted contacts "see" neuronal activity within a radius of only 5-10 mm. Therefore, if the intracerebral electrode is not placed directly in or very close to the epileptic focus, even intracranial EEG recordings can be false negative. For this reason, a careful noninvasive work-up (phase I) is mandatory to prepare optimally for invasive evaluation and increase its yield. The risks of electrode implantation depend on the number of electrodes and sites to be explored; they should be discussed once the implantation strategy is clear. Due to rare occasions of (delayed) infections or bleeding, it is recommended to have round-the-clock in-house access to an intensive care unit and a neurosurgeon on call. 
Surgical outcome
In general, temporal lobe epilepsy carries a better prognosis than extratemporal lobe epilepsy, as a result of less well defined anatomical limits. There is no need to avoid adjacent motor, sensory or language cortices, leading to less limited resection in temporal lobe epilepsy than in extratemporal. Nevertheless, the vast majority of temporal and extratemporal surgical candidates benefit clearly from the surgical procedure. Current surgical approaches are displayed in figure 4 . In our centre, >200 patients have been operated on with the aim of complete seizure control. Overall, 78% were seizure-free at ≥1 year post-operatively and another 8% were almost seizure-free, which amounts to 84% who benefited from the procedure. Ten percent presented moderate seizure decrease or no change (3%). There was no patient with an aggravated seizure disorder after surgery [96] . In a recent review on 40 surgical series between 1995 and 2007, of a total of 3557 patients, 70% of patients with lesional epilepsy were postoperatively seizure-free [102] , confirming the benefit of expert MR imaging and interpretation. Lesions included benign tumours, such as gangliogliomas, and developmental abnormalities, such as dysplasia or gliotic lesions (hippocampal sclerosis, post-traumatic, vascular insult). The outcome of nonlesional and extratemporal cases was markedly poorer, with 40-50% A. 37-year-old patient presenting with seizures with a visual aura in the right visual field. On MRI a left occipital cavernoma was found (à), which was surgically removed (right). Work-up did not show any other focus or area of dysfunction. B. 34-year-old patient presenting with generalized seizures, EEG showed a very active focus in the right frontal lobe, but MRI was considered normal. Right: PET identified a focal hypometabolism in the right frontal lateral area (à). Left: Review of the MRI showed blurring between gray and white matter indicating the presence of a dysplasia. EEG = electroencephalogram; MRI = magnetic resonance imaging; PET = positron emission tomography seizure-free patients. However, in most of the reviewed studies there was no access to PET, ictal SPECT or electric source imaging based on scalp EEG with >100 electrodes (ESI). In our experience, the chances of freedom from seizures are markedly higher in nonlesional epilepsy if a comprehensive work-up is done. For example, with full use of ESI, the number of seizure-free patients with no lesion in the MRI was 80% [103] . Even lesional epilepsy benefits from complementary imaging techniques other than MRI, which can lead to 80-85% being seizure-free, since not only the site but also the extent of the epileptogenic zone needs to be determined [96] . However, precise prognosis for the outcome of surgery can be given only after in-depth evaluation. Finally, not all patients are candidates for surgical resection; in our experience, 20-30% need treatments other than surgery. Once patients have undergone the surgical procedure, they continue to be followed up by their referring neurologist. In about 50% of the cases drug therapy needs to be maintained. However, in most cases, only one drug is sufficient. In the other 50%, drugs can be withdrawn with success. Complete withdrawal should be tried, and it appears that the time-point of withdrawal is irrelevant: it can be tried, for example, after 6 months. Overall, per year 30-40 patients are operated on in Switzerland. However, a conservative estimate (incidence of epilepsy of 50/100'000, 10% surgical candidates) suggests that there should be 400 patients operated per year in Switzerland. This mismatch is observed in most European and North American countries; the reasons are discussed above. In fact, the average epilepsy duration (in adults) on admission for evaluation is in most studies, as at our centre, around 20 years. Such a long duration might compromise surgical success. Shorter epilepsy duration is significantly related to better surgical outcome [104, 105] . Epilepsy surgery is an effective treatment option and the only one able to cure epilepsy. Surgery needs to be considered early in the work-up and not as "last resort" in order to obtain optimal results.
Neuromodulation
Neuromodulation is currently gaining importance for many diseases; the most established indication is the treatment of Parkinson's disease. Regarding epilepsy, two neuromodulatory approaches are currently approved: vagal nerve stimulation and deep brain stimulation (DBS) of the anterior thalamic nuclei (ANT). Other techniques are still being researched and may represent possible future neuromodulatory modalities (transcranial magnetic stimulation, transcranial direct current stimulation, etc.). However, all approaches have in common that <5-10% of implanted patients become seizure-free [106] . Thus, neuromodulation should be considered as a palliative treatment and offered only after the surgical option is ruled out.
Vagal nerve stimulation
The most established among the neuromodulatory techniques is vagal nerve stimulation (VNS). It was approved by the FDA in 1997 for medically refractory epilepsy, and in 2005 also for treatment-resistant depression. The exact mechanisms on how VNS modulates seizures and mood are still not understood, and there are no indicators as to which patients are most likely to benefit. A spiral-shaped electrode is implanted with its end around the vagus nerve in the left jugular cervical region (the right vagus innervates the sinoatrial node) and a pacer device is placed subcutaneously in the left clavicular or lateral thoracic region, similar to a cardiac pacemaker. Stimulation parameters are relatively well established but intensity needs to be progressively adjusted during the following weeks. The most frequently used protocol is the regular stimulation of 30 sec every 5 min. Patients have the possibility to apply additional stimulations with a hand-held magnet, if they feel a typical aura or an imminent seizure. VNS is safe and relatively well tolerated; the most frequent side-effects are a cough during stimulation or brief modification of the voice during the short period of stimulation. A recent review on 74 studies of a total of 3321 patients, including three of class I and two of class II quality, showed that seizure frequency was reduced on average by 45%. Only 4.6% of the patients became seizure free and another 7.6% had a major seizure decrease in the order of >90%. Most patients fall in the category "no change" (49.4%). The remainder experienced some decrease between 50-90% [107] . Open-label studies suggest that these benefits are increased with time and stimulation parameter adjustment [107] [108] [109] [110] , although not all studies report significant effects. It appears that generalised seizures respond better to VNS than partial seizures [107] . A new device, taking into account abrupt onset tachycardia as an indicator of a seizure, may be associated with greater effectiveness. We will see if this translates into higher responder rates. Serious adverse events are very rare (infections, aspiration, cardiac arrhythmias); however, patients with VNS can undergo MRI only in very limited conditions, as outlined by the manufacturer. Also the use of surgical electrocautery in the thoraco-cervical region is only possible with special precautionary measures.
Deep brain stimulation of the anterior thalamus
Deep brain stimulation (DBS) consists of the stereotactic implantation of an electrode into the deep structures of the brain, with a wire to an externally placed pacer similar to VNS. Since early pioneer studies [111] , a number of studies have targeted many brain sites such as the cerebellum [112] [113] [114] , the nonspecific activation system in the centromedial thalamus [115] [116] [117] [118] , the hippocampi [119] [120] [121] [122] [123] , eloquent motor cortex [124] [125] , or caudate nucleus [127] , the subthalamic nucleus [128, 129] . DBS comprises two principal types, the stimulation of a particular site in an automatic fashion and so-called "responsive neurostimulation" of the individual seizure foci (RNS) [126, 130] . Regarding the latter, the electrode which applies the stimulation is also capable of recording and analyzing the EEG and stimulating in a more targeted fashion. RNS, after a randomised double-blinded trial, was approved in the USA in 2013, but is not yet available in Europe. DBS of the anterior thalamus (DBS-ANT) was approved after the SANTE trial in 2010 [131] . The anterior thalamus represents a relay structure of the Papez circuit, which connects the structures of the limbic system such as hippocampus, parahippocampal gyrus and entorhinal cortex with the ipsilateral mammillary body, cingulate cortex and cingulum bundle, and is therefore an entry gate into the epileptogenic limbic circuit. Several favourable pilot studies resulted in the multicentre randomised controlled trial of bilateral stimulation of the ANT for epilepsy (SANTE) in 110 adult patients with focal seizures [131] . Seizure frequency dropped in the first month by 20% for all participants and thereafter significantly by 40% for the active group compared to only 14% in the control group. As in VNS, the effect of stimulation increased over time with a maximum typically seen 1-2 years after implantation, and up to 50-70% seizure reduction after several years [132] . Ten percent of the patients (6/59) were seizurefree for more than 2 years and 16% were without seizures for at least 6 months. Interestingly, better effects were obtained in patients with temporal lobe seizures, most likely due to the fact the ANT is part of the Papez circuit. The main complications originate from the implantation procedure itself. There were also triggered seizures, electrode misplacement and mistargeting causing undesired effects such as stimulation-induced paraesthesias, and memory and mood decrease, but this was usually reversible [131, 132] . 
Conclusions
With so many new antiepileptic drugs we now have a much larger armamentarium to control seizures. Classical and new antiepileptic drugs differ in their profile of side effects. All are equally effective but some of the new AEDs result in weight loss, pain control or decreased anxiety, which may be welcome properties. Newly developed drugs are generally more expensive than established drugs, and this is also true for AEDs. However, fewer side-effects, fewer pharmacological interactions, long half-life / single daily dose regimen and an easier switch between oral and intravenous formulations, if available, may argue in favour using new AEDs. The various drugs differ in their mechanisms of action, which should promote research towards a better understanding of the underlying cellular and molecular mechanisms. We still need to learn more about "good" polytherapy, i.e., which drug combinations are most efficient. If optimal combinations are known, lengthy trial-and-error treatments with low tolerability are avoided. However, in patients for whom the first two AEDs do not control seizures, chances that the third or fourth drug will provide complete seizure control are weak. Already at this point, in-depth evaluation should be requested which may or may not lead to epilepsy surgery. It is not rare that recurrent fits are of nonepileptic origin and/or related to poor compliance, which may be difficult to identify in an outpatient. The most important aspect of epilepsy care is that we should never be content with less than complete seizure freedom. Admittedly this may not be always possible, in particular in patients with neurological deficits or learning disabilities. Certainly, there should always be a cost-benefit analysis, but there is no doubt that a seizure free patient provides the best cost-benefit ratio both for direct medical costs as well as indirect costs for the society (unemployment etc.). A. 37-year-old patient presenting with seizures with a visual aura in the right visual field. On MRI a left occipital cavernoma was found (à), which was surgically removed (right). Work-up did not show any other focus or area of dysfunction. B. 34-year-old patient presenting with generalized seizures, EEG showed a very active focus in the right frontal lobe, but MIR was considered normal. Right: PET identified a focal hypometabolism in the right frontal lateral area (à). Left: Review of the MRI showed blurring between gray and white matter indicating the presence of a dysplasia. EEG = electroencephalogram; MRI = magnetic resonance imaging; PET = positron emission tomography
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